MoonLake Immunotherapeutics annual return on equity
2022
2023
2024
2025
MoonLake Immunotherapeutics Return on Equity (ROE) Growth & History (MLTX)
MoonLake Immunotherapeutics's return on equity was −60.51% for fiscal 2025.
View full MoonLake Immunotherapeutics company overviewMoonLake Immunotherapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −60.51% | −35.27 pp |
| 2024 | 2024-12-31 | −25.24% | −12.01 pp |
| 2023 | 2023-12-31 | −13.22% | +255.07 pp |
| 2022 | 2022-12-31 | −268.29% | — |
MoonLake Immunotherapeutics quarterly return on equity
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −18.12% | −3.61 pp |
| Q1 2026 | 2026-03-31 | −24.96% | −15.61 pp |
| Q4 2025 | 2025-12-31 | −21.04% | −11.29 pp |
| Q3 2025 | 2025-09-30 | −21.70% | −14.69 pp |
| Q2 2025 | 2025-06-30 | −14.51% | −9.94 pp |
| Q1 2025 | 2025-03-31 | −9.35% | −6.72 pp |
| Q4 2024 | 2024-12-31 | −9.76% | −8.14 pp |
| Q3 2024 | 2024-09-30 | −7.02% | −4.95 pp |
| Q2 2024 | 2024-06-30 | −4.56% | −0.75 pp |
| Q1 2024 | 2024-03-31 | −2.63% | +17.18 pp |
| Q4 2023 | 2023-12-31 | −1.62% | +21.15 pp |
| Q3 2023 | 2023-09-30 | −2.06% | +14.96 pp |
| Q2 2023 | 2023-06-30 | −3.81% | +23.76 pp |
| Q1 2023 | 2023-03-31 | −19.81% | +229.29 pp |
| Q4 2022 | 2022-12-31 | −22.77% | — |
| Q3 2022 | 2022-09-30 | −17.02% | +7695.12 pp |
| Q2 2022 | 2022-06-30 | −27.58% | +2687.84 pp |
| Q1 2022 | 2022-03-31 | −249.10% | — |
| Q3 2021 | 2021-09-30 | −7,712.14% | — |
| Q2 2021 | 2021-06-30 | −2,715.41% | — |
MoonLake Immunotherapeutics return on equity trends
Between the periods ended 2022-12-31 and 2025-12-31, MoonLake Immunotherapeutics's return on equity increased from −268.29% to −60.51%, a change of +207.78 percentage points. The latest reported quarter, Q2 2026, shows −18.12%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review MoonLake Immunotherapeutics source filings ↗